F.G. v. CooperSurgical, Inc.

CourtDistrict Court, N.D. California
DecidedMay 20, 2024
Docket4:24-cv-01261
StatusUnknown

This text of F.G. v. CooperSurgical, Inc. (F.G. v. CooperSurgical, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
F.G. v. CooperSurgical, Inc., (N.D. Cal. 2024).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 F.G., et al., Case No. 24-cv-01261-JST

8 Plaintiffs, ORDER GRANTING IN PART AND 9 v. DENYING IN PART MOTION FOR PROTECTIVE ORDER IN PART 10 COOPERSURGICAL, INC., et al., Re: ECF No. 8 Defendants. 11

12 13 Before the Court is Plaintiffs’ motion for a protective order. ECF No. 8. The Court will 14 grant the motion in part and deny it in part. 15 I. BACKGROUND 16 A. Defendants CooperSurgical, Inc. and The Cooper Companies 17 Defendants CooperSurgical, Inc. (“CooperSurgical”) and The Cooper Companies, Inc. 18 (“TCC”) “manufacture, market, and sell products to fertility clinics, including a culture media 19 product designed to support the growth and development of embryos created through [in vitro 20 fertilization].” ECF No. 1 ¶ 2.1 “The culture media is a nutrient-rich liquid that surrounds a 21 fertilized egg during the incubation period to help it develop into a viable embryo as part of the 22 IVF process.” Id. 23 “In December 2023, CooperSurgical recalled certain lots of its culture media products[.]” 24 Id. ¶ 3. The recall notice stated, in part, that “CooperSurgical [had] become aware of a sudden 25 increase in complaints regarding the aforementioned lots of this product,” and acknowledged that 26 the “risk to health is impaired embryo development prior to the blastocyst stage.” Id. ¶ 46. 27 1 “According to regulatory authorities, CooperSurgical issued the recalls because the recalled 2 batches of the Global Media were deficient in magnesium . . . a critical component and essential 3 element of embryo culture media[.]” Id. ¶ 47. “The FDA posted a notice on its website regarding 4 the recall in February 2024, estimating that 994 bottles of culture media were affected, 481 of 5 which were purchased by clinics across the United States.” Id. ¶ 51.2 6 B. Plaintiffs F.G. and H.I. 7 “Plaintiffs F.G. and H.I. are a married couple that sought IVF treatment at a fertility clinic 8 in New York” in the hopes of having biological children. Id. ¶ 4. Plaintiffs bring this action on 9 behalf of themselves and on behalf of a class of “individuals in the United States whose eggs 10 and/or embryos were exposed” to recalled lots of Defendants’ product. Id. ¶ 59. 11 “On or around November 2023, Plaintiffs’ fertility clinic fertilized four of F.G.’s eggs with 12 H.I.’s sperm and placed them in Defendants’ culture media.” Id. ¶ 55. Plaintiffs allege that 13 “[e]ach of the four eggs was successfully fertilized, but all of Plaintiffs’ developing embryos were 14 destroyed due to Defendants’ defective culture media.” Id. ¶ 56. In February 2024, “F.G and H.I. 15 were notified . . . that all of their embryos were exposed to the defective culture media, which was 16 subject to a recall.” Id. ¶ 57. Plaintiffs aver that “[t]he embryos that [they] lost are irreplaceable” 17 because “F.G. is older now than she was at the time the eggs used to create the lost embryos were 18 retrieved.” Id. ¶ 58. As a result, Plaintiffs contend that “even if [they] are able to create additional 19 embryos—a physically, emotionally, and financially costly procedure that is by no means 20 guaranteed to succeed—those embryos made with older eggs would not have as high of a chance 21 of successfully developing into a healthy child or children.” Id. 22 Plaintiffs filed this putative class action against Defendants on March 1, 2024, alleging, 23 inter alia, strict products liability (manufacturing defect, design defect, and failure to warn), 24 negligent failure to recall, negligence or gross negligence, trespass to chattels, and unjust 25 enrichment. ECF No. 1. Including the present case, there are at least 21 cases pending before the 26 undersigned making similar claims against Defendants. 27 1 C. CooperSurgical’s Contacts with Putative Class Members 2 Since January 13, 2024, CooperSurgical has been contacting affected patients through a 3 settlement program that it calls the “Fertility Patient Program.” ECF No. 30 at 7. The 4 communications to affected patients, which are conducted through third-party clinics, indicate that 5 “a lot of global culture media from CooperSurgical” was recalled and that “embryos from your 6 IVF case . . . were exposed to the recalled media.” ECF No. 8-3 at 2. In addition, the 7 communications state that, in order to reach a resolution, the patient must execute a “HIPAA 8 release” to share “cycle and contact information with CooperSurgical.” Id. Although the 9 communications have continued since the filing of this putative class action, there is no evidence 10 that CooperSurgical has advised patients of the existence of the litigation. See ECF No. 8-7 at 2; 11 ECF No. 32-2 at 2. Plaintiffs now bring this motion for a protective order seeking to prevent 12 Defendants from communicating with putative class members. ECF No. 8. Plaintiffs request that 13 the Court “invalidate any releases or settlements the Defendants have procured,” “prohibit 14 Defendants from communicating with class members,” and “furnish Plaintiffs’ counsel with the 15 names of all class members they have contacted directly.” Id. at 9–10. They also ask the Court to 16 order Defendants to distribute a corrective notice. Id. at 10–11. 17 II. JURISDICTION 18 The Court has jurisdiction under 28 U.S.C. § 1332. 19 III. LEGAL STANDARD 20 “Because of the potential for abuse, a district court has both the duty and the broad 21 authority to exercise control over a class action and to enter appropriate orders governing the 22 conduct of counsel and parties.” Gulf Oil Co. v. Bernard, 452 U.S. 89, 100 (1981).3 “The 23 prophylactic power accorded to the court presiding over a putative class action under Rule 23(d) is 24 broad; the purpose of Rule 23(d)’s conferral of authority is not only to protect class members in 25 particular but to safeguard generally the administering of justice and the integrity of the class 26 3 “Although Gulf Oil concerned communications between counsel for the named plaintiff and 27 potential class members, its rationale has been found to apply to communications between 1 certification process.” O’Connor v. Uber Technologies, Inc., No. C-13-3826 EMC, 2014 WL 2 1760314, at *3 (N.D. Cal. May 2, 2014). 3 Gulf Oil mandates that “an order limiting communications between parties and potential 4 class members should be based on a clear record and specific findings that reflect a weighing of 5 the need for a limitation and the potential interference with the rights of the parties.” 452 U.S. at 6 101. “[S]uch a weighing—identifying the potential abuses being addressed—should result in a 7 carefully drawn order that limits speech as little as possible, consistent with the rights of the 8 parties under the circumstances.” Id. at 102. An order under Gulf Oil “does not require a finding 9 of actual misconduct”—rather, “[t]he key is whether there is ‘potential interference’ with the 10 rights of the parties in a class action.” O’Connor v. Uber Technologies, Inc., No. C-13-3826 11 EMC, 2013 WL 6407583 at *4–5 (N.D. Cal. Dec. 6, 2013). 12 Rule 23(d) does not prohibit offers of settlement to putative class members, but courts may 13 limit communications that improperly encourage potential class members to not join the suit, 14 especially if they fail to provide adequate information about the pending class action. See 15 O’Connor, 2014 WL 1760314, at *6–7. The best notice will “contain an adequate description of 16 the proceedings written in objective, neutral terms, that, insofar as possible, may be understood by 17 the average absentee class member.” In re Nissan Motor Corp. Antitrust Litigation, 552 F.2d 18 1088, 1104 (5th Cir. 1977).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gulf Oil Co. v. Bernard
452 U.S. 89 (Supreme Court, 1981)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
United States v. Vinton
594 F.3d 14 (D.C. Circuit, 2010)
Friedman v. INTERVET INC.
730 F. Supp. 2d 758 (N.D. Ohio, 2010)
In Re Currency Conversion Fee Antitrust Litigation
361 F. Supp. 2d 237 (S.D. New York, 2005)
Bublitz V. E.I. Dupont De Nemours & Co.
196 F.R.D. 545 (S.D. Iowa, 2000)
Camp v. Alexander
300 F.R.D. 617 (N.D. California, 2014)
Ehrlich v. Union Pacific Railroad
302 F.R.D. 620 (D. Kansas, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
F.G. v. CooperSurgical, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/fg-v-coopersurgical-inc-cand-2024.